Onco Actu du 23 mars 2017

	3.1 Tabac
Global smoking rates have fallen since introduction of international tobacco control strategy [Cancer Research UK] The research looked at 126 countries, all but 10 of which signed up to the treaty. Smoking rates fell by an average of more than 2.5% in the countries that adopted the framework, a steeper fall than in the other 10 nations.
	3.4 Chimioprévention
Postmenopausal women with a family history of breast cancer should be offered anastrozole, says NICE in updated guidance [NICE] NICE recommends anastrozole is offered for 5 years to postmenopausal women at high or moderate risk of breast cancer unless they have severe osteoporosis. And clinicians should consider offering it to women at moderate risk of breast cancer.
NICE backs use of drugs for breast cancer prevention [PharmaTimes] The cost regulator recommends that doctors prescribe either tamoxifen, raloxifene and now anastrozole to potentially hundreds of thousands of 'healthy' women who have no personal history of breast cancer but have a higher risk of developing it.
	5.2 Pharma
Striving to vanquish leukemia [Novartis] Working with mice with an aggressive form of CML, Novartis scientists tested a carefully designed combination of two molecules—a drug already approved for use in cancer patients, plus an investigational one called ABL001.
	5.2.1 Pharma - Partenariats
GSK and Regeneron to mine gene data from 500,000 Britons [Reuters] By analyzing genetic variations and health in 500,000 middle-aged and older Britons, the partners said on Thursday they hoped to identify promising leads for new medicines.
	5.2.3 Pharma - économie
BioClin raises $30M Series B round for bladder cancer candidate [FierceBiotech] The biotech, which has not been overly communicative (its last formal PR was back in 2015), is working on a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) mAb in a phase 1/2 study in patients with metastatic bladder cancer, or metastatic urothelial carcinoma (mUC), who have relapsed or are refractory to platinum therapy.
BioClin Gets $30M to Back More Bladder Cancer Drug Trials [Xconomy] With the new capital, BioClin says it will test its drug in patients who have metastatic bladder cancer or metastatic urothelial carcinoma and have either relapsed or failed to respond to first-line cancer treatments.
BioClin scores a $30M raise from marquee investors to fuel mid-stage work on a new cancer drug [EndPoints] BioClin is in a Phase Ib/II study of its FGFR3 receptor drug B-701 combined with docetaxel for Stage IV bladder cancer. It’s also prepping a similar stage trial of the same drug combined with Roche’s checkpoint Tecentriq (atezolizumab).
Three considerations for the pharma industry as President Trump focuses on drug pricing [EndPoints] Overall, shifting the focus from individual drug pricing towards pharmacoeconomic value is in the best interest of all stakeholders.
	5.3 Traitements - FDA, EMA, NICE...
Call for experts in anonymisation of clinical data [EMA] EMA to set up technical group in the context of the publication of clinical data.
	5.4 Traitements - Economie
Cost effective but unaffordable: an emerging challenge for health systems [BMJ] Budget impact is essentially the price per patient multiplied by the number of patients treated. Yet the prevalence of someone’s condition should not determine their access to treatment.
	6. Lutte contre les cancers
U.S. Cancer Care System Poised for Transformation, but Challenges Loom Large [ASCO] In “State of Cancer Care in America: 2017,” ASCO Lays Out Vision for Cancer Care Delivery System to Address Growing Patient Population, and Access, Affordability Challenges.
	6.1 Observation
The pill provides 'lifelong protection against some cancers' [NHS Choices] These uncertainties aside, this study provides reassuring news for older women, who may wonder whether the oral contraception they used in their younger years has increased the risk of getting cancer. There's no evidence from this study of an increase in cancer risk – and the reverse may be true for certain types of cancer.
	6.10.1 Politiques (USA)
Slashing the NIH budget won’t keep America first in the fight against cancer [STAT] The NIH pursues research that only the government can take on.
The Need for Publicly Funded Science [Neurologica] Funding is like water in the desert, life will bloom wherever there is water, and will wilt and die without it. A sudden and dramatic cut in funding, such as an 18% decrease for the NIH, is a disaster for our biomedical research infrastructure.
	6.12 Ethique
With patients demanding experimental drugs, ‘right to try’ is becoming the law of the land [STAT] Some physicians, ethicists, and regulatory officials say the laws could harm more patients than they help — but many are reluctant to publicly oppose the laws for fear of being seen as opposing any one patient’s quest to save his or her life.
	6.2 Implants mammaires
Breast Implants Linked To Rare Blood Cancer In Small Proportion Of Women [NPR] A study published earlier this year estimated the lifetime prevalence of ALCL in people with textured implants is 33 per 1 million persons.
FDA links very rare cancer, 9 deaths, to breast implants [STAT] On average, the cancer occurs eight years after a woman gets an implant, according to the American Society of Plastic Surgeons. It noted only about 10 new cases are reported worldwide each year.
	6.5 Médecines alternatives
Naturopaths cynically use the murder of a quack to promote naturopathic licensure [Restpectful Insolence] Basically, Ibrisevic died because she trusted a quack instead of conventional medicine. Yes, she had probably a 50% chance of dying anyway if she had accepted conventional treatment before it was too late, but that’s a 50% chance she didn’t have once she believed Gonzalez’s claims and acted upon them.
	6.6 Publications
Valuing privacy and transparency [ORCID] An ORCID record contains only metadata, so, for example, for a journal article, ORCID stores the title, author list, date, and DOI, but not the article itself. We also do not collect or store sensitive information, such as a user's address, tax ID, or financial or medical information.
On “The Impact Factor Fallacy” [The Scientist] The world of scientific publishing is definitely more complex than can be expressed with a two-digit number. In the end, we still need to read, discuss, and try to understand papers before judging them.